Researchers criticise EMA over trial reporting and access to "commercial" raw data
This article was originally published in SRA
Executive Summary
The European Medicines Agency is again under fire for the way it makes public clinical trial-related information. Researchers writing in the BMJ have criticised how the agency reports Phase III trial results in its European public assessment reports. The criticism comes shortly after the agency defended itself against another BMJ article accusing regulators of putting drug company profits ahead of patient wellbeing when it comes to allowing access to unpublished trial reports.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.